<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324792</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 05 54</org_study_id>
    <nct_id>NCT00324792</nct_id>
  </id_info>
  <brief_title>I3LTE4: Intensive Insulin Therapy and Production of LTE4 in Patients With Diabetes</brief_title>
  <official_title>Effect of an Intensive Insulin Therapy on the Production of LTE4 in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the effect of a 3-month intensive insulin
      therapy on urinary leukotriene E4 (LTE4) excretion in patients with diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our group has recently reported the results of a preliminary cross-sectional study, which
      demonstrated that the urinary LTE4 excretion is increased in patients with type 1 diabetes.
      With regard to recent human genetic studies showing that polymorphisms in the 5-lipoxygenase
      (5-LO) promoter and FLAP haplotypes is linked to cardiovascular disease susceptibility our
      data suggested the potential interest of LTE4 as a non-invasive biomarker of cardiovascular
      risk. In diabetes mellitus, further studies are required to evaluate the 5-LO pathway after
      improvement of glucose control and concomitantly with established inflammatory cardiovascular
      biomarkers.

      The secondary objectives are:

      Before and after 3-month intensive insulin therapy- Relationship between a marker of platelet
      activation (urinary 11-dehydro-thromboxan B2 :11-dehydroTXB2) and urinary LTE4- Relationship
      between inflammatory plasma markers of cardiovascular risk (hs-CRP and fibrinogen) and
      urinary LTE4- Relationship between a plasma marker of endothelial dysfunction (sICAM-1) and
      urinary LTE4- Changes in LTE4 according to patient subgroups (patients with type 1 and type 2
      diabetes mellitus)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in urinary LTE4 excretion and HbA1c after 3-month intensive insulin therapy versus baseline</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary 11-dehydroTXB2</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sICAM-1 plasma levels</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Leucotrienes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intensive insulin therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes mellitus (type 1 or type 2)

          -  &gt; 18 year-old

          -  subject has given free, informed written consent

          -  subject entitled to health insurance cover

          -  medical follow-up at the department of Diabetology, Grenoble University Hospital

          -  inappropriate glucose control (HbA1c &gt; 8.5%) requiring an initiation, or revision, of
             insulin therapy

        Exclusion Criteria:

          -  legal incapacity or limited legal competence

          -  pregnant women

          -  heart failure

          -  impaired renal function,defined by a creatinin clearance &lt; 60 ml/mn according to
             Cockroft formula

          -  asthma

          -  respiratory failure

          -  IV, IM, SC or oral treatment with cortico-steroids for the last 2 months prior to
             baseline

          -  current smoking &gt; cigarettes / day

          -  any infectious disease for the last 2 months prior to baseline

          -  baseline CRP &gt; 20 mg/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Boizel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département d'urologie, néphrologie et endocrinologie-University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hardy G, Boizel R, Bessard J, Cracowski JL, Bessard G, Halimi S, Stanke-Labesque F. Urinary leukotriene E4 excretion is increased in type 1 diabetic patients: a quantification by liquid chromatography-tandem mass spectrometry. Prostaglandins Other Lipid Mediat. 2005 Dec;78(1-4):291-9. Epub 2005 Nov 2.</citation>
    <PMID>16303623</PMID>
  </reference>
  <reference>
    <citation>Hardy G, Vergnaud S, Lunardi J, Peoc'h M, Bessard G, Stanke-Labesque F. 5-lipoxygenase expression and activity in aorta from streptozotocin-induced diabetic rats. Prostaglandins Other Lipid Mediat. 2005 Jan;75(1-4):91-103.</citation>
    <PMID>15789618</PMID>
  </reference>
  <reference>
    <citation>Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, Spigonardo F, Bucci M, Cuccurullo F, Prescott SM, Stafforini DM. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1665-70. Epub 2005 Jun 2.</citation>
    <PMID>15933245</PMID>
  </reference>
  <reference>
    <citation>Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004 Jan 1;350(1):29-37.</citation>
    <PMID>14702425</PMID>
  </reference>
  <reference>
    <citation>Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004 Mar;36(3):233-9. Epub 2004 Feb 8.</citation>
    <PMID>14770184</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2006</study_first_submitted>
  <study_first_submitted_qc>May 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <last_update_submitted>June 11, 2008</last_update_submitted>
  <last_update_submitted_qc>June 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

